RADNOR, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Neumora Therapeutics, Inc. (“Neumora”) ( NASDAQ: NMRA ) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora's prospectus and registration statement (collectively, the “Offering Documents”) issued in connection with Neumora's initial public offering held on or around September 15, 2023. The lead plaintiff deadline is April …

Iron Mountain (IRM -7.28%) didn't quite end its 2024 on a high note, at least as far as its fundamentals were concerned. Thursday morning, the company released its fourth-quarter and full-year 2024 results, and investors weren't all that pleased with them.

SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all purchasers of ICON PLC (NASDAQ: ICLR) ordinary shares between July 27, 2023 and October 23, 2024. ICON is a clinical research organization (CRO).

Apple will bring back TikTok to the App Store after receiving a letter from U.S. Attorney General Pam Bondi, according to Bloomberg, marking the popular app's return to the store nearly a month after a ban against it briefly went into effect.

Wynn Resorts, Limited (NASDAQ:WYNN ) Q4 2024 Results Conference Call February 13, 2025 4:30 PM ET Company Participants Julie Cameron-Doe - Chief Financial Officer Craig Billings - Chief Executive Officer Brian Gullbrants - Chief Operating Officer, North America Linda Chen - President, Wynn Macau Frederic Luvisutto - Chief Operating Officer, Wynn Palace Conference Call Participants Carlo Santarelli - Deutsche Bank Sean Kelley - Bank of America John DeCree - CBRE David Katz - Jefferies Robin Farley - UBS Dan Politzer - Wells Fargo Stephen Grambling - Morgan Stanley Steve Wieczynski - Stifel Brandt Montour - Barclays Chad Beynon - Macquarie …

Electrovaya, Inc. (NASDAQ:ELVA ) Q1 2025 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants John Gibson - CFO Raj DasGupta - CEO Conference Call Participants Daniel Magder - Raymond James Eric Stine - Craig-Hallum Craig Irwin - Roth Capital Jeffrey Campbell - Seaport Research Partners Jeff Grampp - Alliance Global Partners Amit Dayal - H.C. Wainwright Operator Greetings.

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Edison International (NYSE:EIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edison-international-lawsuit-submission-form?prid=129423&wire=1 or contact Joseph E. Levi, Esq.

MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced that it has resumed distribution of EGRIFTA SV ® (tesamorelin for injection), following correspondence from the U.S. Food and Drug Administration (FDA) that allows the Company to release two recently manufactured batches of EGRIFTA SV ® . The product is ready for immediate shipment to network pharmacies.

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Newmont Corporation (NYSE:NEM) between February 22, 2024 and October 23, 2024, inclusive (the "Class Period"), of the important April 1, 2025 lead plaintiff deadline. SO WHAT: If you purchased Newmont securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far produced encouraging Phase 2 data and has an ongoing Phase 3 PROSERA trial for PAH. The main event comes with its topline results in Q4 2025. GOSS's pipeline includes a PH-ILD program slated to start Phase 3 in mid-2025. This program addresses a larger, high-mortality TAM.

Montevideo, Uruguay, Feb. 13, 2025 (GLOBE NEWSWIRE) -- MercadoLibre, Inc. (Nasdaq: MELI) ( http://www.mercadolibre.com ) announces that it intends to release financial results for its fourth fiscal quarter ending December 31, 2024, on February 20, 2025.

Applied Materials, Inc. stock is falling after reporting Q1 2025 earnings. Margin improvement coupled with gradual revenue growth indicate solid long-term fundamentals. Despite some volatile price action, I think AMAT is a stock to hold for the long haul.

Apple will restore ByteDance-owned TikTok on its U.S. App Store on Thursday following a directive from U.S. Attorney General Pam Bondi, Bloomberg News reported on Thursday, citing people with knowledge of the matter.

LIMA, Peru--(BUSINESS WIRE)--Cementos Pacasmayo S.A.A. and subsidiaries (NYSE: CPAC; BVL: CPACASC1) (“the Company” or “Pacasmayo”) a leading cement company serving the Peruvian construction industry, announced today its consolidated results for the fourth quarter (“4Q24”) and for the year (“2024”) ended December 31, 2024. These results have been prepared in accordance with International Financial Reporting Standards (“IFRS”) and are stated in Soles (S/). 4Q24 FINANCIAL AND OPERATIONAL HIGHLIGHT.

ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses (the “Offering”).

ZUG, Switzerland, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses (the “Offering”).

Twilio Inc. (NYSE:TWLO ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Bryan Vaniman - Senior Vice President of Investor Relations and Corporate Development Khozema Shipchandler - Chief Executive Officer Aidan Viggiano - Chief Financial Officer Conference Call Participants James Fish - Piper Sandler Michael Turrin - Wells Fargo Securities Nicholas Altmann - Scotiabank Mark Murphy - JPMorgan Ryan Koontz - Needham & Company Meta Marshall - Morgan Stanley Arjun Bhatia - William Blair Alex Zukin - Wolfe Research Patrick Walravens - Citizens JMP Securities Ryan MacWilliams - Barclays Operator Good day and thank you …

HSBC is preparing to report $1.5 billion of annual cost savings from the changes implemented under its broad restructuring initiatives on February 19, the Financial Times reported on Thursday.

Goodyear (GT) came out with quarterly earnings of $0.39 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.47 per share a year ago.

The headline numbers for Piedmont Office (PDM) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.